 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > NeoRx Corporation
 |
NeoRx Corporation |
 |
 |
 |
NEWS FROM THE WIRES |
 |
NeoRx says Paul Abrams resigns as CEO, president Jul 31 2001 06:26 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
NeoRx develops technology that may make old cancer drugs new again. The company's Pretarget technology enables a variety of tumor-specific antibodies and therapeutic agents to be combined into one treatment. The technology is also designed to allow larger, more potent doses of cancer-killing agents to be used without harming healthy tissue because it is delivery directly to the tumor. NeoRx is using Pretarget to develop treatments for lymphoma, as well as lung, prostate, breast, ovarian, colorectal, and pancreatic cancer. The firm has halted trials of lead drug candidate Skeletal Targeted Radiotherapy, which targets multiple myeloma, a cancer affecting plasma cells in bone marrow, because of delayed side effects.
COMPETITION |
 |
ILEX Oncology, Inc. (ILXO)
ImmunoGen, Inc. (IMGN)
Immunomedics, Inc. (IMMU)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 3.50
1-Yr. Sales Growth: 483.3%
Employees: 72
Revenue per employee: $48,611.11
KEY PEOPLE |
 |
Douglass B. Given
CEO
CONTACT INFO |
 |
410 W. Harrison St.
Seattle, WA 98119
US
Phone: 206-281-7001
Fax: 206-284-7112
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |